2023 is shaping up to be a pivotal year for Aldeyra Therapeutics Inc. (ALDX) as it continues to make significant progress in its pipeline of compounds targeting systemic and retinal immune-mediated diseases.
Two of the company's drug candidates - ADX-2191 and Reproxalap - are under FDA review.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.